De Astis, Enrico <br/><br/>
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.  [electronic resource] 

 -  Annals of hematology  Dec 2014 
 - 2011-8 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1432-0584 
<br/><br/><label>Standard No.: </label>10.1007/s00277-014-2143-8  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Blood Component Transfusion<br/>Combined Modality Therapy<br/>Consolidation Chemotherapy<br/>Cytarabine--administration & dosage<br/>Daunorubicin--administration & dosage<br/>Diarrhea--chemically induced<br/>Drug Administration Schedule<br/>Drug Evaluation<br/>Female<br/>Granulocyte Colony-Stimulating Factor--therapeutic use<br/>Hematopoietic Stem Cell Transplantation<br/>Humans<br/>Kaplan-Meier Estimate<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Liposomes<br/>Male<br/>Middle Aged<br/>Neutropenia--chemically induced<br/>Precursor Cell Lymphoblastic Leukemia-Lymphoma--drug therapy<br/>Proportional Hazards Models<br/>Remission Induction<br/>Retrospective Studies<br/>Salvage Therapy<br/>Vidarabine--administration & dosage<br/>Young Adult